53981-38-7

Basic information

• Product Name: CHROMAN-4-YLAMINE
• Synonyms: AKOS BBS-00006847;AKOS BB-9702;3,4-DIHYDRO-2H-CHROMEN-4-AMINE;3,4-DIHYDRO-2H-CHROMEN-4-YLAMINE;2H-1-BENZOPYRAN-4-AMINE, 3,4-DIHYDRO-;CHROMAN-4-YLAMINE;4-aminochroman;chroman-4-amine
• CAS NO: 53981-38-7
• Molecular Formula: C₉H₁₁NO
• Molecular Weight: 149.19
• Product Categories: Heterocycles series
• Mol File: 53981-38-7.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 237.395 °C at 760 mmHg
• Flash Point: 102.106 °C
• Appearance: /
• Density: 1.106 g/cm³
• Vapor Pressure: 0.0449mmHg at 25°C
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.87±0.20(Predicted)
• CAS DataBase Reference: CHROMAN-4-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: CHROMAN-4-YLAMINE(53981-38-7)
• EPA Substance Registry System: CHROMAN-4-YLAMINE(53981-38-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 53981-38-7(Hazardous Substances Data)

Usage

General Description

CHROMAN-4-YLAMINE, also known as 4-Aminochroman, is an organic compound with the chemical formula C9H11NO. It is a derivative of chroman, a type of organic compound belonging to the class of benzopyrans, and it contains an amine functional group. CHROMAN-4-YLAMINE is used in organic synthesis as a building block for the preparation of various pharmaceuticals and agrochemicals. It has also been investigated for its potential therapeutic applications in the treatment of various medical conditions, including neurodegenerative diseases. Additionally, it is used as a reagent in chemical research and experimentation. Overall, CHROMAN-4-YLAMINE is a versatile chemical compound with various applications in the fields of science and industry.

InChI:InChI=1/C9H11NO/c10-8-5-6-11-9-4-2-1-3-7(8)9/h1-4,8H,5-6,10H2/p+1/t8-/m0/s1

Upstream product

• 90609-63-5 3,4-dihydro-2H-chromene-4-amine hydrochloride 
• 676133-62-3 3,4-dihydro-2H-4-chromenyl azide 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 238764-07-3 tert-butyl N-(3,4-dihydro-2H-4-chromenyl)carbamate 
• 24541-01-3 chroman-4-one oxime 
• 24541-01-3 (4E)-2,3-dihydro-4H-chromen-4-one oxime 

Downstream Products

• 81816-67-3 1-(3,4-dihydro-2H-chromen-4-yl)-4-methylpiperazine 
• 81816-66-2 1-Chroman-4-yl-4-phenyl-piperazine 
• 81816-70-8 1-Chroman-4-yl-4-(4-methoxy-phenyl)-piperazine 
• 81816-69-5 1-Chroman-4-yl-4-(3-methoxy-phenyl)-piperazine 
• 81816-68-4 1-Chroman-4-yl-4-(2-methoxy-phenyl)-piperazine 
• 81816-63-9 Bis-(2-chloro-ethyl)-chroman-4-yl-amine; hydrochloride 
• 735248-42-7 6-bromochroman-4-amine 
• 730980-58-2 2-methoxy-N-((R)-3,4-dihydro-2H-chromen-4-yl)acetamide 
• 1035093-81-2 (4S)-chroman-4-amine hydrochloride 
• 210488-55-4 (R)-chroman-4-ylamine 
• 188198-38-1 (4S)-3,4-dihydro-2H-l-benzopyran-4-amine 
• 1061690-83-2 C₁₆H₁₅NO₂ 
• 903581-19-1 N-(5-fluoro-2-(methylsulfonyl)phenyl)chroman-4-amine 
• 676133-63-4 tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-3-(3,4-dihydro-2H-chromen-4-ylamino)-2-hydroxypropylcarbamate 

Relevant articles and documents

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

Microwave-Enhanced Asymmetric Transfer Hydrogenation of N-(tert-Butylsulfinyl)imines

Microwave irradiation has considerably enhanced the efficiency of the asymmetric transfer hydrogenation of N-(tert-butylsulfinyl)imines in isopropyl alcohol catalyzed by a ruthenium complex bearing the achiral ligand 2-amino-2-methylpropan-1-ol. In addition to shortening reaction times for the transfer hydrogenation processes to only 30 min, the amounts of ruthenium catalyst and isopropyl alcohol can be considerably reduced in comparison with our previous procedure assisted by conventional heating, which diminishes the environmental impact of this new protocol. This methodology can be applied to aromatic, heteroaromatic and aliphatic N-(tert-butylsulfinyl)ketimines, leading, after desulfinylation, to the expected primary amines in excellent yields and with enantiomeric excesses of up to 96 %. Microwave irradiation promotes the asymmetric transfer hydrogenation of N-(tert-butylsulfinyl)imines in 2-propanol catalysed by a ruthenium complex bearing an achiral β-amino alcohol as ligand. After desulfinylation, α-branched primary amines containing aromatic, heteroaromatic and aliphatic substituents are obtained in excellent yields and with enantiomeric excesses of up to 96 %.

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.